Skip to main content

Table 1 Baseline characteristics

From: Analyzing Health-Related Quality of Life Data to Estimate Parameters for Cost-Effectiveness Models: An Example Using Longitudinal EQ-5D Data from the SHIFT Randomized Controlled Trial

Description Standard care
n = 2665 patients
Ivabradine
n = 2648 patients
Mean/freq SE/% Mean/freq SE/%
Demographics
 Age (years) 60.30 0.22 60.63 0.22
 BMI (m2/kg) 28.14   28.13  
 Female 599 22.5% 627 23.7%
Vital signs
 Heart rate (bpm) 79.98 0.19 79.45  
 Systolic blood pressure (mmHg) 121.78   122.25  
 LVEF category
  <26% 622 23.3% 633 23.9%
  ≥26%, <30% 460 17.3% 419 15.8%
  ≥30%, <33% 742 27.8% 705 26.6%
  ≥33% 841 31.6% 891 33.7%
NYHA class
 II 1254 47.1% 1264 47.7%
 III 1361 51.1% 1346 50.8%
 IV 50 1.9% 38 1.4%
Medical history
 HF duration
  <0.6 years 628 23.6% 625 23.6%
  ≥0.6, <2 years 690 25.9% 676 25.5%
  ≥2, <4.8 years 665 25.0% 696 26.3%
  ≥4.8 years 682 25.6% 651 24.6%
 Primary cause of heart failure
  Non-ischemic 809 30.4% 795 30.0%
  Ischemic 1856 69.6% 1853 70.0%
  MI 1564 58.7% 1538 58.1%
  Hypertension 1791 67.2% 1782 67.3%
  Diabetes 820 30.8% 781 29.5%
  Prior stroke 240 9.0% 199 7.5%
Treatment at randomization
 Beta-blocker use
  No beta-blockade 260 9.8% 260 9.8%
  <half target dose 1060 39.8% 1062 40.1%
  ≥half target dose, <target dose 715 26.8% 714 27.0%
  ≥target dose 630 23.6% 612 23.1%
 ACE inhibitors 2110 79.2% 2121 80.1%
 ARBs 355 13.3% 350 13.2%
 Allopurinol 169 6.3% 162 6.1%
 Loop diuretics 2096 78.7% 2109 79.7%
  1. SE standard error, BMI body mass index, bpm beats per minute, LVEF left ventricular ejection fraction, HF heart failure, MI myocardial infarction, ARBs angiotensin receptor blockers